Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome
详细信息 查看全文
- 作者：Yong Won Choa ; neurocho@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Richard P. Allenb ; Christopher J. Earleyb
- 关键词：Restless legs syndrome ; IV ferric carboxymaltose ; Treatment
- 刊名：Sleep Medicine
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：25
- 期：Complete
- 页码：16-23
- 全文大小：1307 K
文摘
- •
A randomized, placebo-controlled study of 1000 mg ferric carboxymaltose (FCM) in restless legs syndrome (RLS) patients was conducted.
- •
FCM recipients had significant improvement in RLS symptoms at the six-week endpoint.
- •
More than one-third of FCM recipients were still not requiring RLS medications at 30 weeks.